期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 8, 期 1, 页码 95-106出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERI.09.123
关键词
critically ill; meningitis; MIC; MRSA; obesity; osteomyelitis; pharmacodynamic; pharmacokinetic; pneumonia; vancomycin
资金
- National Center for Research Resources (NCRR) [KL2RR024983]
- NIH
- NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024983] Funding Source: NIH RePORTER
Vancomycin is a commonly used antimicrobial in patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Increasing vancomycin MIC values in MRSA clinical isolates makes the optimization of vancomycin dosing pivotal to its continued use. Unfortunately, limited data exist regarding the optimal pharmacokinetic-pharmacodynamic (PK-PD) goal to improve bacterial killing and clinical outcomes with vancomycin. The hallmark study in this area suggests that achieving an AUC to MIC ratio of over 400 improves the likelihood of achieving these outcomes. Challenges in the implementation of PK-PD-based dosing for vancomycin include current methodologies utilized in microbiology laboratories, as well as intra- and interpatient pharmacokinetic variability. Individualized dosing based on MIC and specific patient factors is important to achieve optimal outcomes from vancomycin therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据